How clinical trials can become a strategic asset for biotech startups

1. lip 14, 2025

Clinical trials are often seen as a regulatory necessity, but for biotech and medtech startups, they can be much more. In an interview for AIN, Wojciech Kula, CEO of Axcellant, shares why early, well-planned clinical trials are increasingly viewed by investors as a key business advantage.

The conversation touches on some of the most common mistakes made by early-stage teams, particularly underestimating the time and cost required for clinical research. “Every trial needs its tailored strategy,” says Wojciech Kula. “Assuming that similar past studies can simply be reused is one of the fastest paths to delays and frustration.”

Clinical trials are complex for many reasons: recruiting study centers, enrolling patients, and adapting to unpredictable variables all require experience and flexibility. That’s why investors today look closely at the people behind trial design—from statisticians and medical advisors to clinical operations leads. Involving an experienced CRO at the right moment can make a significant difference. The article also explores the emerging role of AI. While not yet capable of replacing human expertise in trial planning, AI already supports data review, trend prediction, and regulatory intelligence, especially in extensive, multi-site studies.

At Axcellant, we help our clients see clinical trials not just as a development stage, but as an opportunity to build credibility, reduce risk, and increase valuation. This perspective enables companies to secure stronger partnerships and achieve a lasting impact.

Read the full interview with Wojciech Kula on AIN.